This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million Jaguar currently owns approximately 73.5% of Napo Therapeutics Napo Therapeutics’ mission is to provide access … Read More
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPA SGI has invested in Spexis as part of the … Read More
The team at Mi-Helper is developing game changing, non-drug treatments for migraine and other pain disorders. The therapy is quick, simple and non-invasive, designed to be self-administered in the comfort of your home.
AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well as addressing the need to delay and overcome resistance to targeted drugs in oncology. … Read More
Fibronostics, a global company providing non-invasive, algorithmic diagnostics for NASH patients, announced today that it has secured $8 million in series A funding. The financing round was led by AT Capital, a leading private investment firm in Asia and Elev8.vc, an early-stage deep-tech VC fund. … Read More
Fibronostics, a global diagnostics company, providing non-invasive, algorithmic diagnostics to detect and manage metabolic diseases, announced today Stephen A. Harrison, MD has joined its board of advisors. … Read More
COVID-19 drug development has brought a unique set of clinical challenges, virtual patient training and decentralized trials can be part of the solution. … Read More
PARIS — June 18, 2020 – ObvioHealth, a full-service virtual research organization (VROTM), announces today a partnership with La Foundation Hôpital Paris Saint Joseph to monitor COVID-19 prevalence and symptoms among the oncology patients of the Groupe Hospitalier Paris Saint … Read More
Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million. … Read More
SPRIM and Health Catalyst partner to jumpstart understanding of COVID-19 impact on NASH and NAFLD population to advance clinical trials for liver disease. … Read More
ObvioHealth, a leading virtual health research organization or VRO, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March. … Read More
Our very own Matty Culbreth- Notaro speaks on Cheddar-TV to breakdown Obvio-19, a virtual research study designed to measure COVID-19 prevalence, symptoms and immune response in the United States. … Read More
ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months. … Read More
Following our three successful past events – June 2017 & January 2019 in Singapore and April 2019 in New York – SPRIM held another exciting Ventures Day at our brand new auditorium in Singapore. Our CEOs, science/tech experts, and strategic innovators presented … Read More
Learn how social media and digital clinical trials were used for recruiting participants in under-represented racial and ethnic groups. … Read More
The need for safe medical devices is mounting. Estimates show that demand for such devices will increase 4.5% annually through 2030, with the United States being the largest market where current spending exceeds 180 billion USD annually. … Read More
SPRIM’s portfolio company, ObvioHealth, conducted a double-blind, randomized clinical trial to study the impact of rice vinegar on blood pressure and vascular reactivity. ObvioHealth focused on recruiting minorities, given that high blood pressure disproportionately impacts the black population in the U.S. … Read More
Despite the emergence of the digital age of recruitment, the standard (aged) approaches to recruitment persist: media advertising (television, newspaper advertisements), physician referrals, press releases/public service announcements, posting fliers, physician referrals, random mailings, and cold calls are all still in play. … Read More
This article explains the emergence of RegTech as an opportunity in the consumer product goods industry, as food and beverage, personal care, pharmaceutical, and cosmetic companies often struggle to stay updated on the regulations in a region or country. … Read More
SPRIM and our portfolio company, Fibronostics, are proud to join the Global Liver Institute (GLI) in raising awareness of non-alcoholic steatohepatitis. … Read More
Ayala Healthcare Holdings announced an investment in SPRIM’s portfolio company, Fibronostics. As part of the partnership, AC Health will launch two Fibronostics products, LiverFAST and HealthFACTR, in its FamilyDOC clinics in the Philippines. … Read More
SPRIM Ventures in partnership with Tikehau Capital is hosting a Ventures Day event in New York on April 24. … Read More
Fibronostics presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore. The event was attended by current and potential investors in the TKS 1 fund, including venture capitalists, strategic investors, family offices and leaders from the healthcare industry. … Read More
Evid Science’s founder and CEO, Matt Michelson, spoke to Thrive Global about the future of healthcare and how AI is transforming the industry. Evid Science is helping to “free” all of the scientific data locked away in publications and journals. … Read More
Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States. … Read More
Going strong in its second time, together with Tikehau Capital, SPRIM held TKS 1 Investor Day on Friday, January 25, 2019, at the Four Seasons Hotel in Singapore. We invited all teams, shareholders, and partners of the ventures for this event … … Read More
RegAsk uses artificial intelligence to answer regulatory questions, including inquiries about path-to-market, path-to-claim, product registration and regulatory strategy. … Read More
ObvioHealth, meanwhile, has developed an app that enables studies to be run using mobile devices. Data from smart devices such as a Bluetooth blood pressure monitor can integrate with the app, according to the company, which earlier this year raised … Read More
MILO & CLAIMIT View a short, imagined study where ObvioHealth’s Milo demonstrates how digital technology improves patient experience, compliance and data capture using ClaimIt. Follow our fictional subject, Milo, as he uses his mobile phone to participate in a clinical … Read More
The blood brain barrier (BBB) is a system of blood vessels that protects the brain from toxins and chemical fluctuations. While it is necessary to help keep the brain healthy, it also poses a problem in delivering medications that could … Read More
Lack of diversity within the clinical trial industry poses a grave problem. We cannot assume medicines work similarly across ethnicities. While attracting and retaining minority groups to participate in clinical trials has become a primary focus in the industry, many … Read More
LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science companies. “Our technology is … Read More
Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based drug discovery company. Travecta plans to use the Duke-NUS technology to develop new … Read More
HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS). Travecta is based on … Read More
LIFE science startups hoping for a big break can now look to a new Singapore-based cash cow for funding.European asset manager Tikehau Capital and Sprim Ventures, the venture arm of global healthcare consultancy Sprim, have teamed up to launch a … Read More
PHILADELPHIA — Sept. 13 2018 – Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, announces it has appointed Douglas … Read More
ORLANDO, Fla.–(BUSINESS WIRE)–ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies— the ObvioHealth app. The app removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, … Read More
ObvioHealth, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding. The company is focused on making clinical trials faster and more cost-effective by digitizing the entire process … Read More